Characteristics | (N = 50) |
---|---|
Age, median (range), years | 50.0 (21–71) |
  < 65 years, n (%) | 46 (92.0) |
  ≥ 65 years, n (%) | 4 (8.0) |
Sex, n (%) | |
 Male | 24 (48.0) |
 Female | 26 (52.0) |
Geographic region, n (%) | |
 USA | 27 (54.0) |
 Europe | 22 (44.0) |
 Asia | 1 (2.0) |
ECOG PS, n (%) | |
 0 | 19 (38.0) |
 1 | 31 (62.0) |
Median time since first diagnosis (range), years | 1.6 (0.2–15.1) |
Median time since last disease progression (range), months | 0.92 (0.33–8.61) |
Number of prior lines of systemic anticancer therapy, n (%) | |
 1 | 13 (26.0) |
 2 | 18 (36.0) |
 3 | 10 (20.0) |
  ≥ 4 | 9 (18.0) |
Receiving concomitant mitotane, n (%) | 25 (50.0) |
PD-L1 expression on tumor cells (≥1% cutoff), n (%) | |
 Negative | 27 (54.0) |
 Positive | 15 (30.0) |
 Not evaluable | 8 (16.0) |
PD-L1 expression on tumor cells (≥5% cutoff), n (%) | |
 Negative | 30 (60.0) |
 Positive | 12 (24.0) |
 Not evaluable | 8 (16.0) |